Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 30, 2011

View Archived Issues

Vaxent and PREVENT to collaborate on group A Streptococcus vaccine

Novel agents show promise against raltegravir-resistant HIV

Synageva BioPharma expands ongoing study in LAL deficiency

Enrollment complete in phase II bavituximab trial in hepatitis C

First patient receives SanBio's novel cell therapy for disability due to stroke

NeuroSearch designs confirmatory phase III Huntexil trial and complementary studies

Aegerion gives update on European filing for lomitapide

Eisai's broad-spectrum antifungal agents display preclinical promise

YM BioSciences starts phase II trial of CYT-387 in myelofibrosis

HTI-501 enters phase I/II trial in women with cellulite

Ibalizumab shows promise in phase IIb study

Phase II trial investigates safety/efficacy of AZD-3199 in COPD

CSIR researchers disclose new antimycobacterial agents

Janssen synthesizes novel series of phosphodiesterase 10A inhibitors

New peptides with antibacterial activity presented by Universitat de Barcelona

Ingenium Pharmaceuticals designs new protein kinase inhibitors

Multifunctional fusion protein prevents HIV infection in vivo

Roche's new-generation glucose test strip receives FDA clearance

Ironwood's European partner Almirall submits linaclotide MAA

Health Canada approves single-pill combination drug for hypertension

JDRF and iCo Therapeutics partner to support phase II iCo-007 study

Dosing begins in proof-of-concept PEDigree trial

NanoCarrier and Kowa to enter worldwide agreement for NC-6300

Biodel announces phase I data on experimental insulins

FDA issues PDUFA target action date for Surfaxin NDA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 2, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...